1-4 of 4
Robert O’Donnell, MD
Close
Sort by
Journal Articles

Correlative Analysis and Clinical Update Of a Phase II Study Using Lenalidomide and Rituximab In Patients With Indolent Non-Hodgkin Lymphoma

Samuel Yamshon, Lihong Qi, PhD, Chaoyu Yu, Xiao-Dong Li, PhD, Robert O'Donnell, MD, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2013) 122 (21): 249.
https://doi.org/10.1182/blood.V122.21.249.249
Published: 2013
Journal Articles

The HB22.7 Anti-CD22 Monoclonal Antibody Is an Effective Platform for CD22-Targeted Antibody Drug Conjugates for Treatment of Lymphoma and Acute Lymphoblastic Leukemia

Soames F. Boyle, MD, Jason Kato, PhD, Robert O'Donnell, MD, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2012) 120 (21): 1653.
https://doi.org/10.1182/blood.V120.21.1653.1653
Published: 2012
Journal Articles

R 2 : Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL).

Mrinal Dutia, MD, Ian DeRoock, MD, Karen Chee, MD, Robert O'donnell, MD, Christine Quirch, Christine Reed-Pease, Joseph Tuscano, MD
Journal: Blood
Blood (2009) 114 (22): 1679.
https://doi.org/10.1182/blood.V114.22.1679.1679
Published: 2009
Journal Articles

The CD22 Epitope, Dose, Dosing Interval, and Timing All Effect Efficacy of Anti-CD22 mAb-Based Therapy of NHL.

Robert O’Donnell, MD, David Pearson, PhD, Hayes McKnight, Thomas Tedder, PhD, Joseph M. Tuscano, MD
Journal: Blood
Blood (2007) 110 (11): 2355.
https://doi.org/10.1182/blood.V110.11.2355.2355
Published: 2007